36results about How to "Reduce ROS levels" patented technology

The invention relates to an application of prussian blue nanoparticles in preparation of drugs for preventing, delaying or treating nervous system degenerative diseases. Researches find that the prussian blue nanoparticles have remarkable effects in the aspects of preventing, delaying or treating nervous system degenerative diseases. Cell level test results show that the prussian blue nanoparticles can reduce the ROS level in nerve cells stimulated by hydrogen peroxide and increase the proportion of living cells in the nerve cells stimulated by hydrogen peroxide; and animal level test resultsshow that the prussian blue nanoparticles can significantly reduce the expression level of oxidative stress markers in hippocampus of nervous system degenerative disease model mice, significantly improve the learning and memory ability of nervous system degenerative disease model mice, and improve dyskinesia. The preparation process of the prussian blue nanoparticles is simple, the macro production is easy, the reaction condition is mild, and the surface modification is easy.

The invention discloses a method for improving the acid stress resistance of candida glabrata, and belongs to the field of bioengineering. The method comprises the following steps: improving the candida glabrata, constructing a gene-deleted mutant strain Cgade12Delta, measuring the intracellular ATP level of the constructed strain, and determining the organic acid tolerance of the strain by a plate growth experiment and cellular activity analysis. After the deletion of the gene CgADE12 is found out, the intracellular ATP level of the strain under the stress of 0.2 percent acetic acid is lowered, the growth capability under the stress of acetic acid is improved, and the acetic acid tolerance is improved.

The invention discloses application of a phospholipid polyethylene glycol modified subminiature cerium oxide nano-enzyme in preparation of a medicine for treating acute kidney injury. The acute kidneyinjury is induced by cis-platinum when cis-platinum is used for treating solid cancer. The phospholipid polyethylene glycol modified subminiature cerium oxide nano-enzyme provided by the invention can present activities of various antioxidant mimic enzymes, can play an efficient catalase activity in a physiological environment, effectively reduces the ROS level by acting on an Nrf2/Keap1 pathway,inhibits cell apoptosis, exerts important protection and treatment effects on acute kidney injury caused by cis-platinum, and is a more promising nanomaterial for low-toxicity anti-tumor applicationand development cis-platinum in clinical practice.

The invention discloses lactobacillus rhamnosus E2 for producing hyaluronic acid and application of the lactobacillus rhamnosus E2, and belongs to the technical field of microorganisms. The preservation number of the lactobacillus rhamnosus E2 for producing hyaluronic acid disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No.21770, and the lactobacillus rhamnosus E2 can produce hyaluronic acid under a fermentation condition. The fermentation supernatant and bacterial suspension of the lactobacillus rhamnosus E2 disclosed by the invention can significantly reduce the level of reactive oxygen in the zebra fish body and significantly improve the activity of superoxide dismutase in the zebra fish body in an in-vivo oxidative stress model, and have the potential of being applied to in-vivo oxidation resistance and senescence delaying; in addition, in a zebra fish injury model, zebra fish tail fin injury repair can be remarkably promoted, and the good potential for promoting tissue injury repair is shown. The lactobacillus rhamnosus E2 disclosed by the invention has a huge potential application prospect in the aspects of resisting oxidation, delaying senescence and promoting tissue damage repair.

The invention provides a use of Pinctada martensii mucus for extracting exosomes, exosomes, an extraction method and application thereof. The invention adopts ultracentrifugation to separate vesicular nanoparticles from Pinctada martensii mucus and identify them as exosomes, which provides a reference for extracting bioactive exosomes from marine organisms and improves the utilization value of Pinctada martensii. The exosomes extracted from the mucus of Pinctada martensii can enhance cell viability, reduce the level of ROS in cells and inhibit NF ‑ 2 κ The activation of B and NLRP3 pathways can reduce the expression level of related inflammatory factor mRNA, which has a certain anti-inflammatory effect.

The invention aims to provide application of rotenone in preparing a medicine for treating diabetic nephropathy to provide a novel candidate compound for treating diabetic nephropathy. Experimental results show that rotenone of a selected dosage has no liver, kidney and heart toxicity; hyperuresis of diabetic nephropathy model mice can be remarkably alleviated, and kidney weight increase, glomerular hypertrophy, impaired renal function, microalbuminuria increase, kidney metabolic disorders and renal fibrosis, caused by STZ, of the mice are reversed.

The invention discloses roxburgh rose pomace combined phenol with remarkable antioxidant activity as well as a preparation method and application of the roxburgh rose pomace combined phenol. The method comprises the following steps: mixing roxburgh rose pomace dry powder with n-hexane, shaking, centrifuging, collecting residues, and drying to obtain degreased roxburgh rose pomace dry powder; mixing the degreased roxburgh rose pomace dry powder with ethanol, and extracting at normal temperature; mixing the obtained residues with a 2-4mol/L NaOH solution, introducing protective gas, sealing, extracting at room temperature for 1-2 hours, adjusting the pH value of the solution to 2-4 by using HCl to obtain a mixed solution, extracting by using ethyl acetate, centrifuging, collecting the ethyl acetate phase, concentrating under reduced pressure, and freeze-drying to obtain the roxburgh rose pomace combined phenol extract. The roxburgh rose pomace combined phenol extract prepared by the invention is high in purity and rich in phenolic substances, has relatively high DPPH and ABTS free radical scavenging ability and oxygen free radical absorption ability, and can also be used in healthy foods or medicines for adjuvant therapy of oxidative stress related diseases.

The invention discloses a preparation method for a pollen pini-radix curcuma antioxidant skin care product. The preparation method comprises the steps of preparation of pollen pini extracts and radixcurcuma extracts, and mixing of the extracts to prepare the antioxidant skin care product. The preparation method has the advantages that the antioxidant skin care product prepared by using the natural extracts from pollen pini and radix curcuma contains no harmful chemical additives, and the antioxidant skin care product can effectively scavenge free radicals, reduce the ROS level, improve the antioxidant enzyme activities, improve the skin elasticity and delay senescence.

The invention relates to the technical field of medicines, in particular to application of a hederagenin derivative in preparation of a hypoxia-reoxygenation injury medicine for myocardial ischemia and reperfusion injury prevention. The compound is stable in a solution; the compound has obvious protective activity against myocardial hypoxia-reoxygenation injury, especially the hypoxia-reoxygenation injury of myocardial ischemia and reperfusion injuries; the myocardium can be well protected from hypoxia-reoxygenation injury when the concentration is 80 micromole/L, and the derivative has stronger pharmacological activity than the parent nucleus hederagenin under the same dosage, so that a new choice is provided for protection against myocardial hypoxia-reoxygenation injury and myocardial ischemia-reperfusion injury.

The invention relates to a pharmaceutical composition containing thymoquinone and dihydromyricetin and application of the pharmaceutical composition to treatment of ovarian cancer, and belongs to thefield of medicines. The pharmaceutical composition contains the thymoquinone and the dihydromyricetin; and the mol ratio of the thymoquinone to the dihydromyricetin is 1 to (0.1 to 10).

The invention discloses an exogenous mitochondrial vector and a compound as well as a preparation method and application of the exogenous mitochondrial vector and the compound; in-vitro exogenous mitochondria is modified by one or more materials with good biocompatibility, a functional gene and/or drug is encapsulated by the modified in-vitro exogenous mitochondria, finally, the two components are jointly delivered to diseased cells to treat mitochondrial defect related diseases. A delivery system is composed of the in-vitro exogenous mitochondria with intact functions, a material with good biocompatibility and the functional gene/drug. Mitochondria mito extracted from autologous or allogenic tissues and cells is subjected to special treatment with the materials with good biocompatibility to form coating-mito, then the coating-mito is mixed and incubated with the functional gene and/or drug according to a certain proportion, and the exogenous mitochondria drug compound is formed through non-covalent acting force. The exogenous mitochondria drug compound can be efficiently taken by damaged cells, and can release normal mitochondria and the related functional gene and/or drug in cytoplasm.

The invention discloses ROS responsive bionic nanoparticles for improving an oxidation microenvironment and a preparation method thereof. The preparation method comprises the steps of immersing cells in a hypotonic solution, centrifuging, ultrasonically treating and freeze-drying to obtain a nanoscale cell membrane; preparing a medicine into a solution I, preparing an ROS responsive polymer material into a solution II, and dropwise adding the solution I into the solution II while carrying out ultrasonic treatment to obtain a mixed solution; adding an emulsifier aqueous solution and the nanoscale cell membrane into a container, and ultrasonically dropping into the mixed solution; and volatilizing the solvent, centrifuging, washing with water, and freeze-drying to obtain the product. The method is simple and low in cost. The ROS response sensitivity is high, the ROS level is reduced, inflammatory response is inhibited, and therefore the pathological microenvironment is improved. The nanoparticles can be more phagocytized by macrophages, excessive ROS and inflammatory factor expression in the cells are reduced, and the bioavailability is high. Animal experiments prove that the nanoparticles have a better disease treatment effect than free drugs, and show a synergistic effect.

The invention discloses an application of an AKT2 inhibitor in the preparation of a medicine for treating a non-alcoholic fatty liver disease, and belongs to the technical field of biological medicines. Pharmacological experiment results prove that the AKT2 inhibitor (CCT128930) has a good treatment effect on an L02 cell lipid deposition model induced by free fatty acid for the first time, lipid deposition in cells and ROS level in cytoplasm are reduced, and Caspase 3 enzyme activity can be reduced, so that cell apoptosis caused by free fatty acid is reduced. The AKT2 inhibitor is used for preparing the medicine for treating the non-alcoholic fatty liver disease, the curative effect is definite, the effect is obvious, the side effect is low, and the medical application prospect is wide.

The invention belongs to the biotechnical field, and concretely relates to a mitochondrial TFAM target conjugate and its application in mitochondrial function stabilization maintenance. A biotin labeled ligustrazine molecule is designed in the invention, and the affinity between streptavidin and biotin is high, so a stable labeled probe-ligustrazine compound plays a role in clinic monitoring and treatment. The TFAM targeting conjugate can be specifically bound with TFAM to protect the TFAM from being degraded by Lon protease, and the mitochondrial stabilization is maintained by reducing the level of ROS in cells and reducing cell apoptosis.

The invention discloses a protective effect of biochanin A on hippocampal neuron cells. The effect of the biochanin A on the injury of primary hippocampal neurons in rats induced by hydrogen peroxideincludes: Bio A preconditioning group can significantly inhibit the injury of hippocampal neurons induced by H2O2; Bio A treatment group can obviously reduce the ROS level in cells; and after Bio A treatment, the invention can up-regulate Bcl-2 protein expression of model cells, and down-regulate Bax and Casepase-3 protein expression dose-dependently.

The invention relates to the technical field of polypeptides, in particular to tripeptide and a preparation method and use thereof. The tripeptide FGF has the amino acid sequence of Phe-Gln-Phe, and the preparation method and the use of the tripeptide are provided. Experiments show that FITC fluorescence intensity of FQF high and low dose groups has significant difference, indicating that FQF cansignificantly reduce the intracellular ROS level and play an antioxidant role. The tripeptide can be widely used in the preparation of drugs or foods inhibiting CD38 enzyme activity, or in the preparation of drugs or foods with anti-oxidation and anti-aging effects.

The invention discloses a saccharomyces cerevisiae engineering strain for high yield of protopanaxadiol and a construction method and use. The construction method of the saccharomyces cerevisiae engineering strain for high yield of protopanaxadiol comprises the following steps: constructing a Pgk1p-YBP1-Cyc1t gene expression cassette, and performing introduction into a ura3 site of a saccharomycescerevisiae engineering strain to obtain the saccharomyces cerevisiae engineering strain W3a-Py for high yield of protopanaxadiol. The experimental results show that the saccharomyces cerevisiae engineering strain for high yield of protopanaxadiol can reduce an intracellular ROS level of the strain by 62.3% (84 h of fermentation), and the yield of protopanaxadiol in a shake flask is increased from1.40 g/L to 1.67 g/L.

The invention belongs to the technical field of plant effective component extraction and application, and discloses application of Citrus chachiensis seed polymethoxylated flavonoid compounds in preparation of antioxidants. The Citrus chachiensis embryo polymethoxylated flavone extract has a protection effect on oxidative damage of cells, can significantly reduce the ROS level in the cells and recover the membrane potential of mitochondria so as to recover the functions of the mitochondria, further reduces oxidative stress damage, shows a good clinical anti-oxidation effect, and has good clinical application prospects. The compound can be applied to various medicines, foods and skin care products with higher requirements on safety, and the oxidation resistance of corresponding products is improved; or independently as an antioxidant; the beverage can also be used as a dietary supplement for removing redundant free radicals in the body and preventing or delaying senescence; or the compound can be used as a medicine or an auxiliary medicine for treating diseases such as neurodegenerative diseases, tumors or inflammations related to oxidative damage.